| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals. 
|
|
Today’s Big NewsOct 2, 2024 |
| By Zoey Becker The company will allow six generic manufacturers to make and sell its long-acting PrEP drug, lenacapivir, in 120 resource-limited countries. |
|
|
|
By Conor Hale Synchron has reported that its miniature Stentrode brain-computer interface implant showed no major side effects in a year-long human safety study. |
By Gabrielle Masson Big Pharma is investing heavily in AI to slash development timelines and foster innovation. But instead of strengthening future relationships with the biotech world, the investment may position independent AI-focused biotechs as a threat to pharma’s internal R&D processes. |
By Kevin Dunleavy A real-world, head-to-head study of two androgen receptor pathway inhibiting (ARPI) prostate cancer drugs indicates that Johnson & Johnson’s Erleada provides an edge in overall survival versus Astellas and Pfizer’s Xtandi. |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
By Kevin Dunleavy Eli Lilly is making another massive investment, revealing it will build a $4.5 billion R&D and manufacturing facility dubbed the Lilly Medicine Foundry that will “drive innovation in drug production and make medicines for clinical trials," the company said. It will add to the huge project the company is constructing in Lebanon, Indiana. |
By Gabrielle Masson Triveni Bio has roped in $115 million to advance preclinical antibody treatments designed to take on immunological and inflammatory disorders. |
By Ben Adams Dermatology biopharma Verrica Pharmaceuticals is lining up a cost-cutting plan that is prompting a major shake-up of its commercial teams and a narrowed focus on how it sells its only approved drug. |
By James Waldron Frazier Life Sciences has sourced a further $630 million for its fund focused on small and mid-cap biotechs. |
By Conor Hale The agency labeled the recall effort as Class I, its most serious, and said it received reports of nine injuries and one death. |
By Andrea Park In a campaign to raise awareness of and testing for the warning signs of esophageal cancer, Lucid Diagnostics is aiming to intercept the disease as early as possible, ideally while it’s still in precancerous stages. |
By Fraiser Kansteiner Aspen is building out a new 22,000-square-foot facility near its headquarters in the Torrey Pines neighborhood of San Diego for the manufacture of induced pluripotent stem cell-derived cell therapies. The new plant is specifically designed for production and testing of Aspen’s personalized Parkinson's disease candidate ANPD001. |
By Darren Incorvaia The COVID-19 pandemic made us acutely aware of how vulnerable our noses are. The nose is a gateway to infection for respiratory pathogens like influenza and SARS-CoV-2, but our options to shield our nasal passageways from disease are limited. |
By Nick Paul Taylor Hologic is asking women to #BustTheMyth this Breast Cancer Awareness Month. The provider of breast health products has put a set of myths about cancer, such as the belief women without a family history have no need to worry, at the center of its latest annual campaign. |
Fierce podcasts Don’t miss an episode |
| In this week's "The Top Line," Fierce journalists discuss key issues from promising but debated lung cancer data at recent conferences. |
|
|---|
|
|
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques. 
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| Submissions Deadline Sept 12th |
|
| Submissions Deadline Sept 12th |
|
|
| |
|
